IRCT20200623047902N17尚未招募未知
Bioequivalence study of Nilotinib 200mg capsule manufactured by Rooyan darou versus Tasigna 200 mg in healthy volunteers in the fasted condition
Rooyan darou company0 个研究点目标入组 24 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 尚未招募
- 发起方
- 入组人数
- 24
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 years 至 55 years（—）
- 性别
- All
入选标准
- •General Health (Liver, Heart, and Kidney)
- •Body Mass Index (18-28)
- •Informed consent
- •Age (18-55 years old)
排除标准
- •History of cardiovascular disease
- •History of liver and kidney disease
- •Alcohol and drug addiction
- •History of allergy to otinib
研究者
相似试验
招募中
不适用
Bioequivalence study of Nilotinib 200mg capsuleThis study is performed on healthy volunteers..IRCT20200623047902N21Zistdaru danesh Co.24
尚未招募
不适用
A bioequivalence study of Niloitinib 150mg capsule of Sobhan Oncology compared to Tasigna 150 mg capsule manufactured by Novartis in 24 healthy volunteers under fasting conditioInvestigation of bioequivalence of Nilotinib 150 mg capsule manufactured by Sobbhan Oncology company in comparison to the Tagigna150 mg capsule manufactured by Novartis company.IRCT20220209053979N4Sobhan Oncology24
招募中
Unknown
Bioequivalence study of Sunitinib 50mg capsuleIRCT20200105046010N75Tabriz University of Medical Sciences24
招募中
Unknown
Bioequivalence study of Linagliptin 5mg tabletIRCT20200105046010N88Tabriz University of Medical Sciences24
尚未招募
不适用
Bioequivalence study of Baricitinib 4mg tabletIRCT20200623047902N24Alborz Zagros company24